01 March 2021

IHH Healthcare

4Q20 India and Acibadem Return to the Black

By Raymond Choo Ping Khoon I pkchoo@kenanga.com.my

FY20 Core Net Profit (CNP) of RM715m (-22% YoY) beat our and consensus expectations by 10% and 34%, respectively. The positive variance from our estimate was due to better-thanexpected performance in India and Acibadem. Specifically, after several quarters in the red, both India and Acibadem turned into the black, prompting us to turn positive. Hence, we upgrade our SoP-TP from RM4.56 to RM5.85 and call from Underperform to Outperform.

Key results' highlights. QoQ, 4QFY20 headline revenue and EBITDA rose 7% and 25%, respectively, due to easing of travel restrictions and lockdowns as patients including elective cases increasingly returned to the group's hospitals. Similarly, EBITDA increased across the board led by strong rebound in inpatient admissions. Overall inpatient admission rose across the board including Singapore (+7%), India (+14%) and Acibadem (+27%). However, inpatient admission in Malaysia fell 6%. This brings 4QFY20 Core Net Profit (CNP) to RM372m (+56%) boosted by: (i) maiden profit recorded in India (4QFY20 core net profit of RM15m compared to 3QFY20 core net loss at RM28m, and (ii) Acibadem registering a maiden profit. A final DPS of 4.0 sen was declared which is within our expectation.

YoY, FY20 revenue and EBITDA decreased 10% and 13%, respectively, due to the pandemic as patients postponed non-urgent and non-essential treatments and visits to hospitals primarily in 2QFY20. The decrease in revenue as a result of lower patient volumes was partially mitigated by COVID-19-related services the Group rendered. Overall, inpatient admission fell across the board including Singapore (-18%), Malaysia (-27%), India (-26%) and Acibadem (-16%). This brings FY20 CNP to RM715m (-22%) due to losses in India.

Outlook. With the gradual easing of local movement restrictions starting in June 2020, the Group has seen local patient volumes recover and occupancy rising to between 45%-75%. Occupancies at the Group's hospitals in Malaysia and Singapore recovered to about 64% and 85% of pre-COVID-19 levels in 4QFY20, respectively. The Group took proactive initiatives to partially mitigate the effects of lower patient volumes by improving case-mix and by providing COVID-19 screening services. COVID-19-related services contributed about 11%, 12% and 21% of the 4QFY20 revenues in Singapore, Central Eastern Europe and India, In Malaysia, the Group's hospitals will allocate respectively. approximately 10% of bed capacity to treat COVID-19 patients and have also taken in non-COVID-19 patients decanted from public hospitals, and will be setting aside about 200 beds for this purpose. We highlight that foreign patient revenues at the Group's hospitals in Turkey exceeded pre-COVID-19 levels in 4QFY20 after Turkey reopened its borders on June 2020. Thus far, the group has further deleveraged its non-lira debt in its Turkish operations from EUR288m as at Dec 2019 to EUR37m as at Dec 2020. The group is hopeful and targeting EBITDA breakeven in Gleneagles HK. In India, the group will continue to drive cost savings and ramped up productivity and room to increase bed occupancy ratio currently averaged 60%. In India, specifically, non-COVID related activities saw month-on-month recovery on inpatient admission. IHH guided that it will try to contain costs for Gleneagles Chengdu while Parkway Shanghai is expected to open in end-2021 or early 2022.

Upgrade from UP to OP. No changes to our FY21E earning forecast. On the back of the positive results from India and Acibadem, we upgrade our SoP-TP from RM4.56 to RM5.85. We roll over our base valuation from FY21 to FY22. We attached a higher EV/Ebitda multiple due to the better outlook.




PP7004/02/2013(031762)

OUTPERFORM †

Price:	RM5.08	
Target Price:	RM5.85	Ť

Share Price Performance



KLCI	1,577.75
YTD KLCI chg	-3.0%
YTD stock price chg	-7.6%

Stock Information

Shariah Compliant	Yes
Bloomberg Ticker	IHH MK Equity
Market Cap (RM m)	44,588.3
Shares Outstanding	8,777.2
52-week range (H)	5.88
52-week range (L)	4.55
3-mth avg daily vol:	3,129,845
Free Float	11%
Beta	0.8

Major Shareholders

Mitsui & Co Ltd	32.9%
Pulau Memutik Ven Sdn Bhd	26.0%
Employees Provident Fund	9.8%

Summary Earnings Table

FY Dec (RMm)	2020A	2021E	2022E
Turnover	13,404.6	14,047.5	15,753.0
PBT	567.5	1,652.0	1,872.1
Net Profit (NP)	288.9	920.3	1,065.6
Core NP	715.3	920.3	1,065.6
Consensus (NP)		972.0	1250.9
Earnings Revision	-	-	New
Core EPS (sen)	7.1	10.5	12.1
Core EPS growth (%)	(32.3)	47.7	15.8
NDPS (sen)	4.0	4.0	4.0
BVPS (RM)	2.48	2.54	2.62
Core PER (x)	71.5	55.2	47.7
PBV(x)	2.1	2.0	1.9
Net Gearing (%)	25.2	29.4	23.3
Net Div. Yield (%)	0.7	0.7	0.7

01 March 2021

Key risk to our call is slower-than-expected recovery from the pandemic.

Result Highlight (YTD)			
FY Dec	2019	2020	Y-o-Y
(RM m)	12M	12M	Chg (%)
Turnover	14,912.5	13,404.6	(10.1)
Parkway Pantai	10,745.2	9,533.9	(11.3)
Acibadem Holdings	3,764.7	3,462.2	(8.0)
IMU Health	259.0	248.7	(4.0)
Plife REIT	347.9	367.0	5.5
Others (Plife REIT inter-segment revenue)	(204.4)	(207.2)	1.4
EBITDA	3,317.7	2,876.7	(13.3)
Parkway Pantai	2,370.7	1,989.2	(16.1)
Acibadem Holdings	853.5	796.1	(6.7)
IMU Health	87.2	75.7	(13.2)
Plife REIT	294.4	309.3	5.1
Others	(78.7)	(134.8)	71.4
Eliminations	(209.3)	(158.6)	(24.2)
Depreciation & amortisation	(1,317.2)	(1,339.4)	1.7
Other operating income	308.6	738.4	139.2
Finance cost	(903.6)	(947.6)	4.9
Finance income	131.3	242.9	84.9
Associates and JV	74.1	18.3	(75.3)
Pretax profit	1,042.7	567.5	(45.6)
Taxation	(527.9)	(361.7)	(31.5)
Minority interest	36.6	83.0	126.7
PATAMI	551.5	288.9	(47.6)
Core net profit	920.7	715.3	(22.0)
Core EPS (sen)	9.5	7.1	(25.0)
EPS (sen)	5.3	2.3	(57.3)
EBITDA margin (%)	22	23	
Parkway Pantai	22	21	
Acibadem Holdings	23	23	
IMU Health	34	30	
Pretax margin (%)	7	4	
Effective tax rate (%)	51	64	

Source : Bursa Malaysia, Kenanga Research



IHH Healthcare

01 March 2021

FY Dec 1Q 2Q 3Q 4Q Coc (RMm) 2020 2020 2020 2020 %chg Turnover 3,555.2 2,565.1 3,518.3 3,766.0 7.0 Parkway Pantai 2,492.6 1,847.0 2,501.8 2,692.5 7.6 Aclbadem Holdings 955.8 613.9 922.7 969.9 5.1 IMU Health 67.3 63.2 5.40. 64.1 18.7 PLife REIT 00.0 2.5 92.2 92.3 0.0 Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 266.0 832.7 1,041.6 25.1 9.19 2.19 Aclbadem Holdings 217.3 74.5 224.1 280.2 25.0 INU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.6 91.6 24.5 0 3.6 Others perati	Result Highlight					
Turnover 3,555.2 2,565.1 3,518.3 3,766.0 7.0 Parkway Pantai 2,492.6 1,847.0 2,501.8 2,692.5 7.6 Acibadem Holdings 955.8 613.9 922.7 969.9 5.1 IMU Health 67.3 63.2 54.0 64.1 18.7 PLife REIT 90.0 92.5 92.2 92.3 0.0 Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 268.0 832.7 1.041.6 25.1 Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (16.1) Depreciation & amortisation <t< th=""><th></th><th>1Q</th><th>2Q</th><th>3Q</th><th>4Q</th><th>QoQ</th></t<>		1Q	2Q	3Q	4Q	QoQ
Parkway Pantai 2,492.6 1,847.0 2,501.8 2,692.5 7.6 Acibadem Holdings 955.8 613.9 922.7 969.9 5.1 IMU Health 67.3 63.2 54.0 64.1 18.7 PLife REIT 90.0 92.5 92.2 92.3 0.0 Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 268.0 832.7 1.041.6 25.1 Parkway Pantai 486.6 178.5 524.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Other operating income 12.7 58.2 112.9 (1.0) (10.9) Finance income 72.7<	(RMm)	2020	2020	2020	2020	%chg
Acibadem Holdings955.8613.9922.7969.95.1IMU Health67.363.254.064.118.7PLife REIT90.092.592.292.30.0Others (Plife REIT inter-segment revenue)(50.5)(51.5)(52.4)(52.8)0.7EBITDA734.4268.0832.71.041.625.1Parkway Pantai486.6178.5596.7727.321.9Acibadem Holdings217.374.5224.1280.225.0IMU Health28.522.812.012.43.8PLife REIT70.473.773.691.624.5Others(16.1)(28.4)(20.4)(16.5)(18.9)Eliminations(52.3)(53.0)(53.3)(53.4)0.3Depreciation & amortisation(324.2)(325.4)(354.9)(334.9)(5.6)Other operating income72.758.2112.9(1.0)(100.9)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Associates and JV1.6(3.6)5.614.7180.4Net profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(20.2)102428 <td< td=""><td>Turnover</td><td>3,555.2</td><td>2,565.1</td><td>3,518.3</td><td>3,766.0</td><td>7.0</td></td<>	Turnover	3,555.2	2,565.1	3,518.3	3,766.0	7.0
IMU Health 67.3 63.2 54.0 64.1 18.7 PLife REIT 90.0 92.5 92.2 92.3 0.0 Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 268.0 832.7 1,041.6 25.1 Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 10.5.6 158.5 295.8 178.5 (39.7) Finance income	Parkway Pantai	2,492.6	1,847.0	2,501.8	2,692.5	7.6
PLife REIT 90.0 92.5 92.2 92.3 0.0 Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 268.0 832.7 1.041.6 25.1 Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (99.7) Finance cost (288.6) (217.4) (375.6) (66.0) (82.4) Finan	Acibadem Holdings	955.8	613.9	922.7	969.9	5.1
Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) (52.8) 0.7 EBITDA 734.4 268.0 832.7 1,041.6 25.1 Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (39.7) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit <	IMU Health	67.3	63.2	54.0	64.1	18.7
EBITDA 734.4 268.0 832.7 1,041.6 25.1 Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (39.7) Finance cost (288.6) (217.4) (375.6) (66.0) (82.4) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit (257.4) (232.0) 396.0 660.9 66.9 Taxati	PLife REIT	90.0	92.5	92.2	92.3	0.0
Parkway Pantai 486.6 178.5 596.7 727.3 21.9 Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (397.7) Finance ost (288.6) (217.4) (375.6) (66.0) (82.4) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit (257.4) (232.0) 396.0 660.9 66.9 9.7	Others (Plife REIT inter-segment revenue)	(50.5)	(51.5)	(52.4)	(52.8)	0.7
Acibadem Holdings 217.3 74.5 224.1 280.2 25.0 IMU Health 28.5 22.8 12.0 12.4 3.8 PLife REIT 70.4 73.7 73.6 91.6 24.5 Others (16.1) (28.4) (20.4) (16.5) (18.9) Eliminations (52.3) (53.0) (53.3) (53.4) 0.3 Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (39.7) Finance ost (288.6) (217.4) (375.6) (66.0) (82.4) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit (257.4) (232.0) 396.0 660.9 66.9 Taxation (109.3) (0.1) (86.8) (76.1) NM Net profit	EBITDA	734.4	268.0	832.7	1,041.6	25.1
IMU Health28.522.812.012.43.8PLife REIT70.473.773.691.624.5Others(16.1)(28.4)(20.4)(16.5)(18.9)Eliminations(52.3)(53.0)(53.3)(53.4)0.3Depreciation & amortisation(324.2)(325.4)(354.9)(334.9)(5.6)Other operating income105.6158.5295.8178.5(39.7)Finance cost(288.6)(217.4)(375.6)(66.0)(82.4)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Parkway Pantai	486.6	178.5	596.7	727.3	21.9
PLife REIT70.473.773.691.624.5Others(16.1)(28.4)(20.4)(16.5)(18.9)Eliminations(52.3)(53.0)(53.3)(53.4)0.3Depreciation & amortisation(324.2)(325.4)(354.9)(334.9)(5.6)Other operating income105.6158.5295.8178.5(39.7)Finance cost(288.6)(217.4)(375.6)(66.0)(82.4)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Acibadem Holdings	217.3	74.5	224.1	280.2	25.0
Others(16.1)(28.4)(20.4)(16.5)(18.9)Eliminations(52.3)(53.0)(53.3)(53.4)0.3Depreciation & amortisation(324.2)(325.4)(354.9)(334.9)(5.6)Other operating income105.6158.5295.8178.5(39.7)Finance cost(288.6)(217.4)(375.6)(66.0)(82.4)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit20102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	IMU Health	28.5	22.8	12.0	12.4	3.8
Ellminations(52.3)(53.0)(53.3)(53.4)0.3Depreciation & amortisation(324.2)(325.4)(354.9)(334.9)(5.6)Other operating income105.6158.5295.8178.5(39.7)Finance cost(288.6)(217.4)(375.6)(66.0)(82.4)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	PLife REIT	70.4	73.7	73.6	91.6	24.5
Depreciation & amortisation (324.2) (325.4) (354.9) (334.9) (5.6) Other operating income 105.6 158.5 295.8 178.5 (39.7) Finance cost (288.6) (217.4) (375.6) (66.0) (82.4) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit (257.4) (232.0) 396.0 660.9 66.9 Taxation (109.3) (0.1) (86.8) (165.5) 90.7 Minority interest 46.9 111.5 0.8 (76.1) NM Net profit (319.8) (120.6) 310.0 419.4 35.3 EPS (sen) (3.9) (1.6) 3.3 4.5 37.8 Core net profit 189.4 (84.2) 238.4 371.8 55.9 EBITDA margin (%) 21 10 24 27 Acibadem Holdings 23 12 <td>Others</td> <td>(16.1)</td> <td>(28.4)</td> <td>(20.4)</td> <td>(16.5)</td> <td>(18.9)</td>	Others	(16.1)	(28.4)	(20.4)	(16.5)	(18.9)
Other operating income 105.6 158.5 295.8 178.5 (39.7) Finance cost (288.6) (217.4) (375.6) (66.0) (82.4) Finance income 72.7 58.2 112.9 (1.0) (100.9) Associates and JV 1.6 (3.6) 5.6 14.7 160.6 Pretax profit (257.4) (232.0) 396.0 660.9 66.9 Taxation (109.3) (0.1) (86.8) (165.5) 90.7 Minority interest 46.9 111.5 0.8 (76.1) NM Net profit (319.8) (120.6) 310.0 419.4 35.3 EPS (sen) (3.9) (1.6) 3.3 4.5 37.8 Core net profit 189.4 (84.2) 238.4 371.8 55.9 EBITDA margin (%) 21 10 24 28 23 12 24 29 IMU Health 42 36 22 19 11 18 </td <td>Eliminations</td> <td>(52.3)</td> <td>(53.0)</td> <td>(53.3)</td> <td>(53.4)</td> <td>0.3</td>	Eliminations	(52.3)	(53.0)	(53.3)	(53.4)	0.3
Finance cost(288.6)(217.4)(375.6)(66.0)(82.4)Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Depreciation & amortisation	• •	(325.4)	(354.9)	(334.9)	(5.6)
Finance income72.758.2112.9(1.0)(100.9)Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Other operating income	105.6	158.5	295.8	178.5	(39.7)
Associates and JV1.6(3.6)5.614.7160.6Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Finance cost	(288.6)	(217.4)	(375.6)	(66.0)	(82.4)
Pretax profit(257.4)(232.0)396.0660.966.9Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Finance income	72.7	58.2	112.9	(1.0)	(100.9)
Taxation(109.3)(0.1)(86.8)(165.5)90.7Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Associates and JV	1.6	(3.6)	5.6	14.7	160.6
Minority interest46.9111.50.8(76.1)NMNet profit(319.8)(120.6)310.0419.435.3EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Pretax profit	(257.4)	(232.0)	396.0	660.9	66.9
Net profit (319.8) (120.6) 310.0 419.4 35.3 EPS (sen) (3.9) (1.6) 3.3 4.5 37.8 Core net profit 189.4 (84.2) 238.4 371.8 55.9 EBITDA margin (%) 21 10 24 28 Parkway Pantai 20 10 24 27 Acibadem Holdings 23 12 24 29 IMU Health 42 36 22 19 Pretax margin (%) (7) (9) 11 18	Taxation	(109.3)	(0.1)	(86.8)	(165.5)	90.7
EPS (sen)(3.9)(1.6)3.34.537.8Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Minority interest	46.9	111.5	0.8	(76.1)	NM
Core net profit189.4(84.2)238.4371.855.9EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	Net profit	(319.8)	(120.6)	310.0	419.4	35.3
EBITDA margin (%)21102428Parkway Pantai20102427Acibadem Holdings23122429IMU Health42362219Pretax margin (%)(7)(9)1118	EPS (sen)	(3.9)	(1.6)	3.3	4.5	37.8
Parkway Pantai 20 10 24 27 Acibadem Holdings 23 12 24 29 IMU Health 42 36 22 19 Pretax margin (%) (7) (9) 11 18	Core net profit	189.4	(84.2)	238.4	371.8	55.9
Acibadem Holdings 23 12 24 29 IMU Health 42 36 22 19 Pretax margin (%) (7) (9) 11 18	EBITDA margin (%)	21	10		28	
IMU Health 42 36 22 19 Pretax margin (%) (7) (9) 11 18		20	10	24	27	
Pretax margin (%) (7) (9) 11 18	Acibadem Holdings				29	
	IMU Health	42	36	22	19	
Effective tax rate (%) (42) (0) 22 25	Pretax margin (%)	(7)	(9)	11	18	
	Effective tax rate (%)	(42)	(0)	22	25	

Source : Bursa Malaysia, Kenanga Research

Sum-of	-parts val	uation
--------	------------	--------

	Basis	Multiples (x)	Value (RM m)	Remarks
PPL	EV/EBITDA	18.00	37,233	Previously 17x
Acibadem (60%)	EV/EBITDA	17.00	15,370	Previously 16x
Fortis (31.1%)	Market value		2700	Market value
IMU	EV/EBITDA	11.00	638	Premium to peers due to higher earnings base.
International	EV/EBITDA	11.00	341	In line with peers average.
Plife REIT (35.8%)			1,461	
Total			57,744	
Net debt			(6,502)	
Total			51,242	
No of shares (m)			8,769	
Target price (RM)			5.84	
Source: Kenanga Re	search			



IHH Healthcare

01 March 2021

Peer Comparison																	
Name	Last Price	Market Cap	Shariah	Current		enue owth		arnings wth	PER (x) - Core E	arnings	PB\	/ (x)	ROE (%)	Net DivYld (%)	Target Price	Rating
	(RM)	(RM'm)	Compliant	FYE	1-Yr. Fwd.	2-Yr. Fwd.	1-Yr. Fwd.	2-Yr. Fwd.	Hist.	1-Yr. Fwd.	2-Yr. Fwd.	Hist.	1-Yr. Fwd.	1-Yr. Fwd.	1-Yr. Fwd.	(RM)	
HEALTHCARE				10/0001		10 101	oo =0(4 - 004							0.00/		
IHH HEALTHCARE BHD KPJ HEALTHCARE BERHAD	5.08 1.00	44,588 4,279.9	Y Y	12/2021 12/2021	4.8% 12.9%	12.1% 7.7%	28.7% 28.1%	15.8% 14.0%	71.5 32.1	55.2 25.0	47.7 22.0	2.1 1.9	2.0 1.8	4.2% 7.5%	0.8% 2.0%	5.85 1.00	OP MP
PHARMANIAGA BERHAD	4.25	1,112.2	Ŷ	12/2020	-2.4%	-2.7%	34.6%	-4.0%	24.6	18.2	19.0	3.3	3.0	17.1%	2.8%	3.15	UP
Source: Bloomberg, Kenanga Researc	h																

The rest of the page is intentionally left blank



01 March 2021

Stock Ratings are defined as follows:

Stock Recommendations

OUTPERFORM	: A particular stock's Expected Total Return is MORE than 10%
	: A particular stock's Expected Total Return is WITHIN the range of -5% to 10%
UNDERPERFORM	: A particular stock's Expected Total Return is LESS than -5%

Sector Recommendations***

OVERWEIGHT	: A particular sector's Expected Total Return is MORE than 10%
NEUTRAL	: A particular sector's Expected Total Return is WITHIN the range of -5% to 10%
UNDERWEIGHT	: A particular sector's Expected Total Return is LESS than -5%

***Sector recommendations are defined based on market capitalisation weighted average expected total return for stocks under our coverage.

This document has been prepared for general circulation based on information obtained from sources believed to be reliable but we do not make any representations as to its accuracy or completeness. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may read this document. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees. Kenanga Investment Bank Berhad accepts no liability whatsoever for any direct or consequential loss arising from any use of this document or any solicitations of an offer to buy or sell any securities. Kenanga Investment Bank Berhad and its associates, their directors, and/or employees may have positions in, and may effect transactions in securities mentioned herein from time to time in the open market or otherwise, and may receive brokerage fees or act as principal or agent in dealings with respect to these companies.

Published and printed by:

KENANGA INVESTMENT BANK BERHAD (15678-H)

Level 17, Kenanga Tower, 237, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia Telephone: (603) 2172 0880 Website: <u>www.kenanga.com.my</u> E-mail: <u>research@kenanga.com.my</u>

